.Nature Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a median consequence of 11 months, people with metastatic intestinal cysts who got biomarker-matched treatments based upon distributing cyst DNA profiling revealed a more significant scientific advantage than those obtaining unrivaled treatment.